Press Releases

All Releases
View Summary Merrimack Pharmaceuticals Presents on Multiple Programs at the 26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
Nov 21, 2014
PDF 25.5 KB Add to Briefcase
View Summary Merrimack Pharmaceuticals Receives FDA Fast Track Designation for MM-398 in Post-Gemcitabine Metastatic Pancreatic Cancer
Nov 19, 2014
PDF 19.2 KB Add to Briefcase
View Summary Photo Release -- Merrimack Pharmaceuticals Announces the Addition of Vivian S. Lee, Dean of University of Utah School of Medicine, to Its Board of Directors
Nov 17, 2014
PDF 75.3 KB Add to Briefcase
View Summary Merrimack Pharmaceuticals to Present Advances on Targeted Cancer Molecules at the 2014 EORTC-NCI-AACR Symposium
Nov 13, 2014
PDF 17.5 KB Add to Briefcase
View Summary Merrimack Pharmaceuticals Reports Third Quarter 2014 Financial Results
Nov 10, 2014
PDF 25.3 KB Add to Briefcase
View Summary Merrimack Pharmaceuticals Announces Initiation of Phase 1 Clinical Study of MM-398 for Brain Cancer
Nov 6, 2014
PDF 20.6 KB Add to Briefcase
View Summary FDA Grants Orphan Drug Designation to Merrimack Pharmaceuticals' MM-141 for the Treatment of Pancreatic Cancer
Nov 5, 2014
PDF 17.8 KB Add to Briefcase
View Summary Merrimack Pharmaceuticals Announces Timing of Third Quarter 2014 Investor Conference Call
Nov 3, 2014
PDF 15.1 KB Add to Briefcase
View Summary Merrimack Pharmaceuticals Presents Additional Phase 2 Biomarker Data Further Strengthening the Finding That MM-121 Increases Progression Free Survival in Patients With Biomarker Positive Metastatic Breast Cancer
Sep 30, 2014
PDF 24.4 KB Add to Briefcase
View Summary Baxter and Merrimack Pharmaceuticals Enter into Exclusive Ex-U.S. Licensing Agreement to Develop and Commercialize Novel Cancer Compound MM-398
Sep 24, 2014
PDF 19.8 KB Add to Briefcase
View Summary Merrimack Pharmaceuticals to Present Clinical and Biomarker Data on Novel Antibody Therapeutics at the ESMO 2014 Congress
Sep 19, 2014
PDF 20.4 KB Add to Briefcase
View Summary Merrimack Pharmaceuticals Announces Initiation of HERMIONE, a Randomized Trial of MM-302 in Patients With Advanced HER2-Positive Breast Cancer to Support Application for Accelerated Approval
Aug 11, 2014
PDF 18.7 KB Add to Briefcase
View Summary Merrimack Pharmaceuticals Reports Second Quarter 2014 Financial Results
Aug 11, 2014
PDF 22.9 KB Add to Briefcase
View Summary Merrimack Pharmaceuticals Announces Timing of Second Quarter 2014 Investor Conference Call
Aug 4, 2014
PDF 14.9 KB Add to Briefcase
View Summary Merrimack Pharmaceuticals Presents Data From Phase 3 NAPOLI-1 Study at the ESMO 16th World Congress on Gastrointestinal Cancer
Jun 25, 2014
PDF 25.2 KB Add to Briefcase
View Summary Merrimack Pharmaceuticals to Regain Worldwide Rights to Develop and Commercialize MM-121
Jun 19, 2014
PDF 20.9 KB Add to Briefcase
View Summary Merrimack Pharmaceuticals Announces Oral Presentation of Additional Data Results in Phase 3 NAPOLI-1 Study at the ESMO 16th World Congress on Gastrointestinal Cancer
Jun 17, 2014
PDF 20.4 KB Add to Briefcase
View Summary Merrimack Pharmaceuticals Presents Phase 1 Clinical Data Supporting Four Novel Antibody Therapeutic Programs at the 2014 ASCO Annual Meeting
Jun 2, 2014
PDF 22.3 KB Add to Briefcase
View Summary Merrimack Pharmaceuticals Identifies Heregulin as Patient Response Biomarker for MM-121 and Standard of Care Therapy Across Multiple Cancers
Jun 2, 2014
PDF 120.1 KB Add to Briefcase
View Summary Merrimack Pharmaceuticals to Present at the Jefferies 2014 Global Healthcare Conference
May 27, 2014
PDF 15.5 KB Add to Briefcase
Showing 1-20 of 141 Page: 1 2 3 4 5 ... 8  Next 20
Add to Briefcase = add release to Briefcase

Stock Quote (NASDAQ: MACK)

Price:
9.03

Change:
- 0.07

Day High:
9.26

Day Low:
8.95

Volume:
1,996,400

4:00 PM ET on Nov 21, 2014
Delayed ~20 min. By eSignal.

Shareholder Tools